Cited by 226Amyotrophic Lateral Sclerosis ResearchGenetic Neurodegenerative DiseasesAlzheimer's disease research and treatments

CRISPR–Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity

Open access
Kramer, Nicholas J., Haney, Michael S., Morgens, David W., Jovičić, Ana, Couthouis, Julien, Li, Amy, Ousey, James, Ma, Rosanna +8 more·2018·Nature Genetics

Published version of a preprint

Abstract

Hexanucleotide-repeat expansions in the C9ORF72 gene are the most common cause of amyotrophic lateral sclerosis and frontotemporal dementia (c9ALS/FTD). The nucleotide-repeat expansions are translated into dipeptide-repeat (DPR) proteins, which are aggregation prone and may contribute to neurodegeneration. We used the CRISPR-Cas9 system to perform genome-wide gene-knockout screens for suppressors and enhancers of C9ORF72 DPR toxicity in human cells. We validated hits by performing secondary CRISPR-Cas9 screens in primary mouse neurons. We uncovered potent modifiers of DPR toxicity whose gene products function in nucleocytoplasmic transport, the endoplasmic reticulum (ER), proteasome, RNA-processing pathways, and chromatin modification. One modifier, TMX2, modulated the ER-stress signature elicited by C9ORF72 DPRs in neurons and improved survival of human induced motor neurons from patients with C9ORF72 ALS. Together, our results demonstrate the promise of CRISPR-Cas9 screens in defining mechanisms of neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41588-018-0070-7

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cancer cell line screens have limitations for neurological disease research, including that most neurological diseases involve specific cell types, that disease-relevant genes may not be expressed in the line, and that survival control differs between cancer and untransformed cells.

    “Even though such screens have been able to uncover genes that were then validated in relevant cell types such as neurons63,65,68, they have obvious limitations for the study of neurological disease.”

    From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [68]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kramer, N. J., Haney, M. S., Morgens, D. W., Jovičić, A., Couthouis, J., Li, A., Ousey, J., Ma, R., Bieri, G., Tsui, C. K., Shi, Y., Hertz, N. T., Tessier-Lavigne, M., Ichida, J. K., Bassik, M. C., & Gitler, A. D.
Affiliations
  • Stanford Medicine (US)
  • Genentech (US)
  • University of Southern California (US)
  • Stanford University (US)
Corresponding author
  • Bassik, Michael C.
  • Gitler, Aaron D.
Venue
Nature Genetics
Published
2018-03-05
Volume
50
Issue
4
Pages
603-612
ISSN
  • 1061-4036 (ISSN-L)
  • 1546-1718
OpenAlex
W2949846456
Cited by
226
References
81
Citations by year
2026: 12 · 2025: 18 · 2024: 20 · 2023: 38 · 2022: 19 · 2021: 36 · 2020: 29 · 2019: 35 · 2018: 17 · 2017: 1
FWCI
20.04
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Genetics (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Science Foundation
  • Johns Hopkins University
  • Target ALS
  • National Institutes of Health (1dp2hd084069-01)
  • National Human Genome Research Institute (T32HG000044)
  • National Institute of General Medical Sciences (T32GM007790)
  • National Institute of Neurological Disorders and Stroke (R01NS097850, P30NS069375, R35NS097263)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (DP2 HD084069)
  • Robert Packard Center for ALS Research, Johns Hopkins University
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
C9orf72, dipeptide repeat proteins, hexanucleotide repeat expansion, amyotrophic lateral sclerosis, frontotemporal dementia, CRISPR/Cas9 genome-wide screen, endoplasmic reticulum stress, nuclear transport, proteasome, RNA processing, chromatin modification, neurodegeneration
MeSH terms
C9orf72 Protein, rab7 GTP-Binding Proteins, Amyotrophic Lateral Sclerosis, Animals, HeLa Cells, Humans, Membrane Proteins, Motor Neurons, Thioredoxins, Microsatellite Repeats, K562 Cells, rab GTP-Binding Proteins, Active Transport, Cell Nucleus, DNA Repeat Expansion, Mice, Gene Knockout Techniques, Frontotemporal Dementia, Endoplasmic Reticulum Stress, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review